Skip to main content

Table 3 Expected clinical outcomes per patient after treatment with Pregabalin or Gabapentin

From: Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting

  Treatment  
  Pregabalin (150–600 mg/d) Gabapentin (2400 mg/d) Difference (Pregabalin - Gabapentin)
Pain score
     Pre-treatment 6.9 (0.0) 6.9 (0,0) 0.0 (0.0)
     Post-treatment 4.1 (0.0) 4.8 (0,0) -0.6 (0.0)
Days with
     No or mild pain 36 (0.3) 27 (0.3) 9 (0.5)
     Moderate pain 32 (0.3) 38 (0.3) -6 (0.5)
     Severe pain 15 (0.2) 19 (0.3) -4 (0.3)
Days with
     ≥30% reduction in pain score 50 (0.3) 42 (0.4) 8 (0.5)
     ≥50% reduction in pain score 36 (0.3) 26 (0.4) 10 (0.5)
Quality-adjusted life-years (QALYs) 0.1178 (0.0002) 0.1115 (0.0002) 0.0063 (0.0003)
  1. Results presented as Mean (SE) for the 12 – week duration of modeling.